Sign inJoin waitlistJoin the waitlist

Emily Curran

Senior Advisor and Medical Director, Clinical Trials Office · University of Cincinnati Medical Center Inc.

Credentials: · · · · ·

History

Clinical Trials Office · University of Cincinnati Medical Center Inc.
Present
University of Cincinnati Medical Center Inc.
Present
University of Cincinnati Medical Center Inc.
Present

Hematology and Medical Oncology
University of Chicago Medical Center
2011–2014
Internal Medicine
University of Chicago Medical Center
2008–2011
Stanford University School of Medicine
2004–2008
Stanford University (Human Biology
2000–2004

Research

STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia
Cell Reports · 2016 · First of 8 authors · 151 citations
How I treat acute lymphoblastic leukemia in older adolescents and young adults
Case report · Blood · 2015 · First of 2 authors · 108 citations
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial
Clinical Cancer Research · 2014 · 108 citations

Wendy Stock
21 papers
Alice Mims
11 papers
Joshua Zeidner
10 papers
Anjali Advani
9 papers
Olatoyosi Odenike
9 papers
Tara Lin
9 papers
ET
Elie Traer
8 papers
ES
Eytan Stein
8 papers
Gary Schiller
8 papers
JB
John Byrd
8 papers
Maria Baer
8 papers
Rebecca Olin
8 papers

Clinical trials

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Principal investigator · Completed · Phase 1
Boryung Pharmaceutical Co., Ltd
2020–2023
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Site PI · Recruiting
Tempus AI
2026–2035
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2024–2027
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2019–2027